US panel endorses more unproven if buzzy peptides

MedicalXpress | juil. 25, 2026

A U.S. review panel on Friday recommended loosening restrictions on all but one of a buzzy class of peptides, dismissing protests from medical experts who say none are well studied enough to justify wide access.